(Q51647923)

8 April 2018

title

Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. (English)

1 reference

8 April 2018

0 references

1 reference

2

C Blomqvist

1 reference

8 April 2018

I Elomaa

1

1 reference

8 April 2018

P Gröhn

3

1 reference

8 April 2018

L Porkka

4

1 reference

8 April 2018

A L Kairento

5

1 reference

8 April 2018

K Selander

6

1 reference

8 April 2018

C Lamberg-Allardt

7

1 reference

8 April 2018

T Holmström

8

1 reference

8 April 2018

language of work or name

English

0 references

publication date

1 January 1983

1 reference

8 April 2018

published in

The Lancet

1 reference

8 April 2018

volume

1

1 reference

8 April 2018

issue

8317

1 reference

8 April 2018

page(s)

146-149

1 reference

8 April 2018

Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Parenteral diphosphonates for treating malignant hypercalcemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Albumin standards and the measurement of serum albumin with bromcresol green

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Modifications of a specific assay for hydroxyproline in urine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

1 reference

7 January 2021

Evidence for the secretion of an osteoclast stimulating factor in myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Mechanisms of bone destruction in the development of skeletal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Direct resorption of bone by human breast cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Assessment of progression of secondary bone lesions following cancer of the breast or prostate using serial radionuclide imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

Long term effects of dichloromethylene diphosphonate in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2883%2992755-1

7 January 2021

10.1016/S0140-6736(83)92755-1

Identifiers

DOI

1 reference

8 April 2018

1 reference

8 April 2018